Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipid A phosphate head groups are essential components of the lipopolysaccharide (LPS) molecule, which constitutes the outer leaflet of the outer membrane in Gram-negative bacteria [6, 16]. These negatively charged phosphate groups are critical for maintaining the structural integrity of the bacterial cell envelope by coordinating divalent cations like magnesium and calcium [9, 20]. This arrangement creates a robust permeability barrier against hydrophobic antibiotics and detergents [5, 19]. In clinical medicine, these phosphate groups serve as the primary binding site for polymyxin antibiotics, such as colistin and polymyxin B [1, 8]. The electrostatic interaction between the cationic drugs and the anionic phosphates leads to the displacement of stabilizing cations, resulting in membrane destabilization and bacterial cell death [2, 12]. Furthermore, Lipid A is the 'endotoxin' portion of LPS, responsible for triggering potent inflammatory responses and septic shock through the activation of the human TLR4/MD-2 receptor complex [10, 15].
Polymyxin antibiotics, such as colistin and polymyxin B, target the negatively charged phosphate groups of lipid A through electrostatic interactions [1, 2, 5]. This binding displaces divalent cations (calcium and magnesium) that normally stabilize the lipopolysaccharide (LPS) layer in the outer membrane [3, 6, 8]. The resulting destabilization increases membrane permeability, allowing the drug to penetrate and disrupt the inner cytoplasmic membrane, ultimately leading to the leakage of cellular contents and bacterial cell death [2, 3, 12].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide (LPS) lipid A phosphate groups (LPS lipid A phosphate).